Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (Nasdaq: SLP) is frequently in the news for developments at the intersection of biosimulation software, cheminformatics, and AI‑enabled drug development. Company press releases cover its role as a global leader in model‑informed and AI‑accelerated drug development, highlighting how its software and services support pharmaceutical and biotechnology organizations throughout the drug lifecycle.
News items commonly include quarterly and annual financial results, where Simulations Plus reports revenue contributions from its software and services segments, discusses demand trends, and provides guidance ranges for future periods. Management commentary often addresses bookings in software and services, adoption of cloud deployment and AI‑driven workflows, and the impact of market conditions on client spending.
Investors following SLP news will also see announcements about product strategy and AI initiatives, such as the company’s integrated, AI‑enabled modeling ecosystem connecting platforms like GastroPlus®, MonolixSuite®, ADMET Predictor®, and QSP/QST tools. Releases describe cloud‑scale compute, AI copilots that guide complex modeling workflows, and an AI‑orchestrated framework designed to support multi‑engine simulations and decision support.
The company’s news flow includes scientific and collaboration updates, for example validation of AI‑driven drug design in ADMET Predictor® through collaborations and published case studies, and commentary on alignment with regulatory guidance for model‑informed nonclinical safety assessments. Additional items cover investor events such as conference presentations and virtual Investor Day sessions that provide detail on long‑term strategy, product roadmaps, and financial outlook.
By monitoring the SLP news page, readers can track how Simulations Plus communicates its financial performance, advances in biosimulation and AI, regulatory‑aligned modeling capabilities, and strategic initiatives within the biopharma technology landscape.
Simulations Plus (Nasdaq: SLP) has launched RENAsym version 1A, a quantitative systems toxicology software aimed at predicting drug-induced kidney injuries. This new platform expands the company's capabilities beyond liver safety, enhancing its consulting services for drug developers. RENAsym helps identify risks associated with new therapeutics and key biochemical events related to kidney injury, supporting critical go/no-go decisions in drug development. The platform was developed with funding from the National Institutes of Health.
Simulations Plus, Inc. (Nasdaq: SLP) has launched version 9.8.2 of its GastroPlus software, enhancing its modeling and simulation capabilities in the pharmaceutical sector. Key updates include new enzyme expression levels, improved solubility models, and physiology models for better dosing translation. The enhancements aim to streamline workflows and improve user experience, reflecting feedback from the GastroPlus User Group and partnerships with industry leaders. The company emphasizes its commitment to innovation in drug development tools over its 25-year history.
Simulations Plus, Inc. (NASDAQ: SLP) has been awarded a funded contract by the FDA in collaboration with the University of Connecticut. This contract aims to enhance mechanistic in vitro/in vivo correlation (IVIVC) methods for long-acting injectable (LAI) formulations. Dr. Diane Burgess and her lab will generate data for marketed LAI products, while Simulations Plus will develop physiologically based models to establish bioequivalence, potentially reducing regulatory burden. This collaboration marks a significant step in advancing modeling and simulation technology in drug development.
Simulations Plus, Inc. (Nasdaq: SLP) reported a 12% year-over-year revenue increase to $46.5 million for fiscal 2021, with software revenue rising 28% to $27.7 million. In Q4, total revenue was $9.8 million, a 3% increase, while software revenue grew 14% to $5.4 million. Despite a 7% decline in services revenue, gross profit was $7.1 million with a 72% gross margin. For fiscal 2022, the company projects total revenue between $51 million and $53 million, indicating 10% to 15% growth.
Simulations Plus (NASDAQ: SLP) has launched a new University+ Program offering free access to its modeling and simulation software for one year to students and educators at accredited universities worldwide. This initiative celebrates the company's 25th anniversary and aims to enhance education in Modeling and Simulation (M&S). Eligibility for renewal is available under certain conditions. The program seeks to prepare future scientists for careers in drug development and related fields, fostering academic research and collaboration.
Simulations Plus, Inc. has declared a quarterly cash dividend of $0.06 per share on its common stock. This dividend will be paid on November 1, 2021, to shareholders recorded as of October 25, 2021. Future dividends will be assessed quarterly based on earnings, financial condition, and capital requirements. Simulations Plus has been a leader in modeling and simulation software for drug discovery and development for 25 years, serving various industries globally.
Simulations Plus, Inc. (NASDAQ: SLP) will report its fourth quarter and full year financial results for fiscal year 2021, concluding on August 31, 2021, after market close on October 25, 2021. A conference call will follow at 5:00 PM ET that day, allowing stakeholders to discuss financial outcomes and future strategies. The call can be accessed via registration or dial-in. This announcement signifies an important upcoming milestone for the company in detailing its financial performance and operational updates.
Simulations Plus has received a cooperative agreement from the FDA, providing $250,000 annually for two years to enhance its GastroPlus® platform. This funding aims to improve the Transdermal Compartmental Absorption and Transit (TCAT™) model for better simulations of dermal formulations. The project will involve collaboration with leading pharmaceutical and research organizations, focusing on developing innovative strategies for regulatory assessments. This initiative strengthens the company's position in drug modeling and simulation, particularly in dermatology.
Simulations Plus, Inc. (Nasdaq: SLP) announced the release of version 10.3 of its ADMET Predictor platform, now marketed as APX.3. This update introduces enhanced AI capabilities, including a new AI-driven Drug Design Module that integrates third-party calculations for compound optimization. Key improvements include an updated CYP metabolism model and the MedChem Studio™ accessibility for all users, designed to bolster data visualization and analysis. The features aim to expand the client base and maintain double-digit revenue growth as the company enters its 2022 fiscal year.
Simulations Plus, Inc. (Nasdaq: SLP) announced that CEO Shawn O’Connor will present at the BofA Securities 2021 Tech Solutions for Drug Discovery Conference on September 20, 2021, at 10:00 a.m. ET, and at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 22, 2021, at 9:55 a.m. ET. One-on-one meetings will also be held at both events. Live webcasts and presentations will be accessible via the Investors page of the Simulations Plus website for 90 days.